For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Markel Group Inc. (MKL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-13): Designation Watch · Gem Score +24 (−100…+100 Quality+Value blend) · Quality 60 · Value 0 · Sentiment -4 (timing only, not weighted) · Composite fair value $2,494.59 vs $1,842.98 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Markel Group Inc.
MKL NYSEMarkel Group Inc. is a diversified financial holding company focused on specialty insurance, reinsurance, investing, and a portfolio of operating businesses. Through its insurance operations, Markel provides tailored property and casualty coverage for niche commercial risks, along with program services, fronting solutions, and insurance-linked securities capabilities. Its investment activities support the broader insurance platform by managing capital across public and private markets. The company also owns controlling interests in businesses across industrial, consumer, and financial services markets through its Markel Ventures segment. Markel Group serves customers in the United States and international markets, with operations structured to give its businesses a high degree of independence while contributing to a broad, multi-segment financial platform.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 169.22
Total Equity: $19.10B
Shares: 12,451,306
Total Debt: $4.30B
Cash: $3.96B
EBITDA: N/A
Total Debt: $4.30B
Cash: $3.96B
Revenue: $16.33B
Revenue: $16.33B
Revenue: $16.33B
Total Equity: $19.10B
Tax Rate: 21.2%
Equity: $19.10B
Total Debt: $4.30B
Cash: $3.96B
Current Liabilities: N/A
Long-Term Debt: $4.30B
Total Debt: $4.30B
Total Equity: $19.10B
Shares: 12,451,306
Shares: 12,451,306
CapEx: -$206.89M
Shares: 12,451,306
Stock Price: $1,843
Net Income: $2.11B
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 4, 2026 5:12am (39d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $12.9B | $11.8B | $15.7B | $16.8B | $16.3B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $1.5B | $2.2B | $2.2B | $2.3B | $2.3B |
| Operating Income | — | — | — | — | — |
| Net Income | $2.4B | -$216.3M | $2.0B | $2.7B | $2.1B |
| EBITDA | — | — | — | — | — |
| EPS | $176.92 | $-23.57 | $147.32 | $199.69 | $169.74 |
| EPS (Diluted) | $176.51 | $-23.57 | $146.98 | $199.32 | $169.22 |
Balance Sheet (Annual)
Last updated: Sep 4, 2026 5:00am (39d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.0B | $4.1B | $3.7B | $3.7B | $4.0B |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $48.4B | $49.8B | $55.0B | $61.9B | $68.9B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $4.4B | $4.1B | $3.8B | $4.3B | $4.3B |
| Total Liabilities | $33.3B | $36.1B | $39.5B | $44.4B | $49.8B |
| Total Equity | $15.2B | $13.7B | $15.5B | $17.5B | $19.1B |
| Retained Earnings | $10.4B | $9.8B | $11.4B | $13.4B | $15.0B |
Cash Flow (Annual)
Last updated: Sep 4, 2026 5:28am (39d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.3B | $2.7B | $2.8B | $2.6B | $2.8B |
| Capital Expenditure | -$145.2M | -$254.7M | -$258.6M | -$255.0M | -$206.9M |
| Free Cash Flow | $2.1B | $2.5B | $2.5B | $2.3B | $2.6B |
| Acquisitions (net) | -$517.4M | -$79.0M | -$3.6M | -$207.8M | -$106.2M |
| Net Debt Issued / (Repaid) | $711.8M | -$221.0M | -$324.7M | $537.5M | -$29.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$206.5M | -$290.8M | -$445.5M | -$572.7M | -$429.5M |
| Net Change in Cash | -$335.7M | $340.6M | -$889.5M | -$139.8M | $411.1M |
Growth Trends (YoY %)
Last updated: Sep 4, 2026 5:12am (39d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -8.6% | +33.0% | +6.6% | -2.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | — | — | — | — |
| Net Income Growth | -108.9% | +1,022.9% | +37.6% | -23.3% |
| EBITDA Growth | — | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-09-12 02:03A +1σ run of quarters pays +157%; a −1σ run costs 63%. Ratio 2.5:1 (μ 1.7%, σ 20.2% , 16 pairs).
Older method (repeat-worst-quarter): 1.5 : 1
| Case | Growth | Margin | Fair value | vs price ($1,842.98) |
|---|---|---|---|---|
| Bull — recovery | -0% | 19.8% | $2,813.18 | +53% |
| Base — stabilizes | -1% | 17.3% | $2,444.37 | +33% |
| Bear — keeps slipping | -1% | 14.7% | $2,084.59 | +13% |
| Stress — last quarter repeats | +0% | 7.4% | $1,199.63 | -35% |
| Upside — a +1σ run of quarters (v2) | +22% | 16.2% | $4,731.06 | +157% |
| Stress — a −1σ run of quarters (v2) | -19% | 8.1% | $688.24 | -63% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-04 05:41The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a lumpier story than the archetype "mature earner" suggests. Q1 2026 printed a $212M net loss on $3.55B revenue, and Q1 2025 was barely breakeven at $122M NI on the same revenue base — this is not steady compounding, it's an insurance-plus-mark-to-market P&L where a $1.17B Q2 2026 (29% margin) offsets a Q1 hole. Trailing four quarters run roughly $15.5B revenue and $2.28B NI, giving ~$170 EPS against a $1,843 price — 10.8x, matching the tagged P/E. Book value per share sits near $1,533 (equity $19.1B / ~12.4M shares) so P/B is closer to 1.20x, which is where Markel has traded through most soft-cycle windows. 2024 NI of $2.75B was the peak; 2025 fell 23% to $2.11B, and the 2026 run-rate is tracking flat-to-down. Revenue CAGR of 2% is real — this is not a growth story, it's a book-value compounder that has stalled.
The synthesis verdict of $2,965 fair value (+60.9%) is where I part ways with the models. That number leans on a DCF that appears to normalize earnings above what the last eight quarters actually produced, and it ignores that Markel's own peer group (Berkshire at ~1.5x book, W.R. Berkley at ~2.5x book, RLI at ~3.5x book) prices Markel at a discount for a reason: Ventures ROIC is opaque, the insurance combined ratio has been middling versus specialty peers, and Gayner's capital allocation over the last five years has not visibly outperformed. A 38% gap to "intrinsic value" that has persisted for years is not a mispricing waiting to close — it's the market's standing verdict on capital allocation quality. I find the Market Forces "neutral, ~10x normalized" read more defensible than the synthesis composite.
The contrarian case against my own skepticism: at 1.2x book with $2.55B FCF, $3.96B cash against $4.30B debt, and a buyback authorization Markel has historically used opportunistically, downside is genuinely bounded. If Ventures EBITDA (roughly $500M run-rate, buried in segments) were spun or separately disclosed, the SOTP would likely print above $2,200. The 2022 -$216M NI year was a mark-to-market artifact from the equity portfolio, not underwriting failure, and 2023-2024 recovered fully — so the "structural impairment" bear read is probably too harsh. Insider activity is functionally zero (7 shares, 3 shares, 2 shares — these are administrative), which is neither a vote of confidence nor a warning; for a Gayner-led shop where insiders already hold meaningfully, that's noise. The narrative layer correctly identifies this as "anchored, quiet-quality" — there is no story premium to unwind, only a story discount that could compress if Ventures gets disclosed better or if a hard market re-emerges.
Where the data is genuinely thin: no gross or operating margin disclosure in the annual pull, no segment breakout, and the "recent earnings YoY -23.3%" is measured off a tough Q3 2024 comp ($905M NI) that included investment gains — so the deceleration is overstated. FCF CAGR of 0.5% is the honest signal; this business is not growing FCF, full stop. My verdict: the synthesis $2,965 target is too aggressive by 25-35%; a more defensible fair value is $2,100-$2,300, roughly 1.35-1.45x book, which would still imply 15-25% upside from $1,843 without requiring heroic Ventures re-rating. That's a starter-position setup, not a table-pound, and it depends on either (a) a hard-market combined-ratio print below 92 in the next two quarters, or (b) any concrete Ventures disclosure/monetization event. Absent either, this drifts sideways at 1.2x book for another year — which is fine if you're getting paid to wait via buybacks, and Markel has been buying back stock, just not aggressively enough to force a re-rating. Partial agreement with synthesis direction, dissent on magnitude.
GPT Reading
What stands out to me is that the stock is being valued like an ordinary insurer while the reported earnings stream is anything but ordinary. At $1,843, Markel trades at 1.2x book and 10.9x trailing earnings on $19.1B of equity and $2.11B of 2025 net income, with debt of $4.30B largely offset by $3.96B of cash. That is not an expensive starting point for a business that produced $2.76B of operating cash flow and $2.55B of free cash flow in 2025. But the more important point is that the income statement is visibly lumpy: quarterly net income swung from -$212M in 1Q26 to +$1.17B in 2Q26 on nearly identical revenue bases of $3.55B and $4.02B. That tells you the market is right not to annualize any single quarter, but it also tells you a plain P/E is probably understating normalized earning power if mark-to-market noise or catastrophe volatility is depressing confidence. Across the last four full years excluding the ugly 2022, net income was $2.42B, $2.00B, $2.75B, and $2.11B. That is not a broken earnings base.
The revenue line is less exciting than the earnings line, but that is normal for this kind of company. Annual revenue was $16.75B in 2024 and $16.33B in 2025, basically flat to down 2.5%, and the reported revenue CAGR of 2% says this is not a top-line growth story. The equity case has to rest on underwriting discipline, investment income, and capital allocation rather than premium growth. On that score, the data are good enough to lean bullish. A business earning roughly 11% ROE at just 1.2x book does not need heroic assumptions to justify a higher price; even a stable 10-12% ROE insurer-compounder should not obviously sit at a discount to more commoditized carriers if balance sheet leverage is low. Markel’s debt-to-equity of 0.23 is conservative, and net debt is minimal. If the company can continue to convert accounting earnings into cash at anything close to 2025’s $2.55B FCF, the market is over-penalizing near-term cyclicality.
I also think the “mature earner” label is directionally right but too conservative in spirit. Mature earners usually deserve low multiples when there is little reinvestment runway and mediocre returns. Markel still has an embedded reinvestment engine through float, investments, and retained earnings. The market cap is $22.8B against $19.1B of equity, so the market is assigning only about $3.7B of franchise value over book to a business that has shown it can earn north of $2B annually in normal environments. That spread feels too thin unless one believes recent softness is structural. Put differently, if normalized earnings are even $1.8B-$2.1B, today’s price is roughly 10-12x earnings for a conservatively financed insurer-conglomerate, which is attractive rather than merely fair. I do not buy the valuation model’s $2,965 target literally, but I do think it is directionally closer to right than the neutral market-forces take. My own fair value is lower than that model, but still comfortably above the current quote.
The best bear case is that the market is not missing anything; it is correctly discounting a low-growth, increasingly average insurer with a muddier capital-allocation story than its admirers admit. The hard evidence for that case is real. Revenue has gone nowhere, from $15.71B in 2023 to $16.75B in 2024 and back down to $16.33B in 2025. Earnings CAGR of 2.7% and FCF CAGR of 0.5% are not compounder statistics. Recent momentum is negative, with latest quarterly revenue down 2.5% year over year and earnings down 23.3%. Annual net income in 2025 fell to $2.11B from $2.75B in 2024, and 1Q26’s loss reminds you how quickly the optics can deteriorate. If underwriting margins are structurally tightening and investment gains are doing more of the heavy lifting, then 1.2x book is not cheap, it is appropriate. A skeptic would also say that “Berkshire-like” is the most dangerous phrase in finance: if Ventures and investments are a black box and not earning superior returns, the conglomerate structure deserves a discount, not a premium.
What would change my mind is not another quarter of noisy GAAP income by itself, but evidence that normalized returns on equity are slipping below 9% without a compensating acceleration in book value growth or cash generation. If 2026 annualized results start pointing to sub-$1.5B earnings power, or if operating cash flow falls materially below the $2.76B level seen in 2025, then the stock is not obviously cheap even at 1.2x book. Conversely, if the next few quarters show that 1Q26 was transient and Markel can sustain quarterly profitability in the $500M-$700M range with stable equity growth, I would become more constructive and push fair value toward $2,200-$2,400. Right now, the discount is real, but it is a quality discount rather than a distress discount, and I think the market has leaned too far toward skepticism.
Grok Reading
Markel at $1,843 screens cheap on almost every conventional yardstick that matters for a float-funded conglomerate. Trailing P/E of 10.9x on $2.11B of 2025 net income, 1.20x book against $19.1B of equity, and an 11.2% free-cash-flow yield on $2.55B of FCF leave little room for a permanent-impairment story. The balance sheet is clean—$4.3B of debt against $4.0B of cash and a 0.23 debt-to-equity ratio—so leverage is not the issue. Quarterly revenue has held in a tight $3.5–4.0B band for six straight quarters even as net income swung from a $212M loss in Q1 2026 to a $1.17B profit in Q2; that volatility is mark-to-market investment noise, not underwriting collapse. Annual revenue slipped only 2.5% from $16.75B to $16.33B while operating cash flow stayed robust at $2.76B. For a specialty P&C writer that still generates double-digit ROE (11.0%) and converts nearly all of it to free cash, the market is pricing near-zero real growth and mediocre capital allocation forever. That is too punitive relative to the cash the business is actually throwing off.
The numbers tell a mature-earner story, not a value trap. Revenue CAGR of roughly 2% and earnings CAGR of 2.7% over the measured window are slow, yet the absolute dollar machine remains large and the float continues to compound inside a low-cost liability structure. Markel Ventures is opaque, but the consolidated free-cash-flow quality is labeled strong and capex is only $207M against $2.76B of operating cash—hardly the profile of a capital-destructive black box. At 1.2x book the stock sits below the historical Berkshire-like range the pre-flight note itself cites; the 38–60% gap to the composite fair-value estimates ($2,773–$2,965) is therefore less narrative froth than a measurable discount to current earning power.
The strongest counter-argument is that the market is correctly reading a soft-cycle compression and capital-allocation fatigue. 2025 net income already fell 23% year-over-year from the $2.75B peak, recent earnings CAGR is only 2.7%, and Q1 2026 produced a loss. Specialty insurance margins are cyclical; if the hard-market tailwinds that buoyed 2023–24 reverse, underwriting ROE could drift toward mid-single digits and the investment book could deliver only Treasury-like returns. In that world the 10.9x multiple is fair, not cheap, and the Ventures portfolio’s illiquidity discount is permanent. I weigh this less heavily because free-cash-flow generation did not collapse with reported earnings, the balance sheet can absorb a multi-year soft market, and 1.2x book already embeds the skeptic’s view. A true structural impairment would show up first in sustained negative underwriting cash flow—something the latest annual numbers do not show.
I would flip to neutral or bearish if 2026 full-year underwriting combined ratios push above 100% on a sustained basis, if free cash flow falls below $1.8B, or if management begins large, low-IRR Ventures acquisitions that dilute book value growth below mid-single digits. Conversely, two consecutive quarters of clean underwriting profit plus evidence of double-digit Ventures returns would justify a re-rating toward 1.4–1.5x book and remove the last of the discount.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Markel generates durable free cash flow ($2.13B, $2.45B, $2.53B, $2.34B, $2.55B across 2021-2025) on revenue that has scaled from $12.9B to $16.3B. Net income is lumpier ($2.42B, -$216M, $2.00B, $2.75B, $2.11B) because reported earnings absorb mark-to-market on the large equity portfolio, but the cash generation underneath is remarkably steady — a hallmark of a well-underwritten insurance operation compounding float. Diluted share count has actually declined at a -2.4% CAGR, meaning per-share value is being concentrated rather than diluted, and liquid cash of $3.96B (17% of market cap) provides real optionality.
Verify before trusting this (5)
- Combined ratio and reserve development in the insurance segment across 2021-2025
- Segment mix between insurance underwriting, Markel Ventures operating businesses, and investment income
- Composition and concentration of the equity investment portfolio driving GAAP NI swings
- Holdco vs. subsidiary debt structure and interest coverage
- Actual buyback dollars vs. share issuance for comp to confirm the -2.4% share CAGR is genuine repurchase not just optics
The composite fair value of $2,772 and signal-adjusted $2,964 imply 50-60% upside from $1,843, but I discount that headline. The DCF at $3,252 is doing heavy lifting and is the least reliable input for an insurance holdco where float economics and mark-to-market equity gains distort cash flows; the anchored PE at $1,813 basically says the stock is already at its earnings-based fair value. Splitting the difference and giving weight to the Solid (60) quality grade, deserved value sits somewhere in the $2,100-2,400 range - a meaningful but not heroic 15-30% discount, not the 61% upside the synthesis advertises.
Verify before trusting this (5)
- Ventures segment operating income and capital deployed - is ROIC actually accretive
- Insurance underwriting margin trend and combined ratio in specialty lines
- Look-through earnings excluding mark-to-market equity gains
- Buyback pace and per-share book value growth trajectory
- Any activist or breakup-value commentary
MKL sits in the least sentiment-sensitive corner of the market: low beta (0.66), specialty insurance, quiet-quality archetype with a medium cult and moderate intensity. The risk-on tape (VIX 14.3, S&P near highs) barely touches this name - it neither benefits from euphoria nor gets punished by stress. Macro headwinds from a 4.79% 10y and a 25.8 market PE weigh generically on equities but insurance float economics are relatively insulated, and MKL's book is not rate-sensitive in a directionally scary way here.
Verify before trusting this (4)
- Any specialty P&C pricing-cycle commentary suggesting margin compression is accelerating
- Markel Ventures earnings disclosures or a segment-transparency push that could re-rate the sum-of-parts
- Sector rotation into defensive financials on any VIX spike
- Analyst target revisions - currently quiet, a break either way would matter
A softening specialty P&C pricing cycle after a multi-year hard market, with capital abundant and property rates decelerating, is the dominant force. Higher-for-longer rates (10y 4.79) are a genuine positive here: they raise the earnings power of float and reward an insurer willing to write less at worse prices. Casualty severity inflation and litigation finance are the offsetting structural threat to reserve adequacy across the industry. For Markel specifically, the world is arranging itself so that investment income does the growing while underwriting does the disciplining — a holding pattern, not a decline, unless the share gap persists into the next hard market.
When we made this prediction on Sep 4, 2026, MKL was $1,836.88. We expect it to be $2,150.00 by Mar 2027, and we consider it great value under $1,650.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 4, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips down 25%
trailing_eps
flips up 25%
adjusted_pe
flips up 25%